Date: Thursday, December 15, 2016
Time: Approximately 9:30 am MDT
Webcast Link: http://services.choruscall.ca/links/resverlogixagm20161215.html
The presentation will be available on the Company's website immediately prior to the start of the meeting. Click on this LINK to go directly to the appropriate page on the Company's website. An archived replay of the webcast will also be available on the Company's website by clicking on this LINK.
Resverlogix has received an extension from the Toronto Stock Exchange to hold its Annual and Special Meeting of Shareholders on December 15, 2016.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
SOURCE Resverlogix Corp.